孕三烯酮胶囊联合丹黄祛瘀胶囊治疗子宫肌腺病的临床研究

发布时间：2018-07-10 05:53

本文选题：子宫肌腺病 + 孕三烯酮胶囊　；参考：《中国临床药理学杂志》2017年10期

【摘要】：目的观察孕三烯酮胶囊联合丹黄祛瘀胶囊治疗子宫肌腺病的临床疗效及安全性。方法 122例子宫肌腺病患者随机分为对照组及试验组,各61例。对照组予以口服孕三烯酮胶囊2.5 mg,qd,于月经第1,3天各1次,之后每周2次口服(间隔3~4天口服一次);试验组在对照组基础上,予以口服丹黄祛瘀胶囊1.6 g,bid,2组患者均治疗6个月。比较2组患者治疗前后血清糖类抗原125(CA125)、苗勒氏管抑制物(MIS)水平、子宫体积、痛经症状积分、总有效率及药物不良反应发生率。结果治疗后,试验组总有效率为91.81%(56/61例),对照组为72.13%(44/61例),差异有统计学意义(P0.05)。治疗后,试验组和对照组血清CA125分别为(76.34±7.85),(68.57±7.67)U·mL~(-1),MIS水平分别为(4.27±0.52),(6.53±0.85)ng·mL~(-1),子宫体积分别为(120.38±9.13),(111.36±8.74)cm~3,痛经症状积分分别为(8.32±1.02)分,(5.74±0.73)分,差异均有统计学意义(P0.05)。对照组和试验组出现的药物不良反应有潮热盗汗、恶心、痤疮、下肢浮肿,药物不良反应的发生率分别为45.91%(28/61例)和26.23%(16/61例),差异有统计学意义(P0.05)。结论孕三烯酮胶囊联合丹黄祛瘀胶囊能够显著降低子宫肌腺病患者的血清CA125水平,提高血清MIS水平,缩小子宫体积,减轻痛经症状,提高临床疗效和安全性。
[Abstract]:Objective to observe the clinical efficacy and safety of pregnenone capsule combined with Danhuang Quyu capsule in the treatment of uterine myoadenopathy. Methods 122 patients with myometriosis were randomly divided into control group and experimental group with 61 cases each. The control group was given oral pregnancy trienone capsule 2.5 mg / kg QD, once every 3 days after menstruation, and the experimental group was treated with Danhuang Quyu capsule 1.6 gbubido capsule once a week for 6 months on the basis of the control group. Serum carbohydrate antigen 125 (CA125), Mullerian tube inhibitor (MIS) level, uterine volume, dysmenorrhea symptom score, total effective rate and incidence of adverse drug reactions were compared between the two groups before and after treatment. Results after treatment, the total effective rate was 91.81% (56 / 61 cases) in the trial group and 72.13% (44 / 61 cases) in the control group. The difference was statistically significant (P0.05). After treatment, the levels of serum CA125 were (76.34 卤7.85), (, 68.57 卤7.67) U mL ~ (-1), (4.27 卤0.52), (, 6.53 卤0.85) ng mL ~ (-1), (120.38 卤9.13), () 111.36 卤8.74 cm ~ (3), (8.32 卤1.02) and (5.74 卤0.73), respectively. The incidence of adverse drug reactions in the control group and the experimental group were 45.91% (28 / 61 cases) and 26.23% (16 / 61 cases), respectively, with statistical significance (P0.05). The adverse drug reactions were hot and hot sweating, nausea, acne, edema of lower limbs, and the incidence of adverse drug reactions were 45.91% (28 / 61 cases) and 26.23% (16 / 61 cases), respectively (P0.05). Conclusion pregnancy trienone capsule combined with Danhuang Quyu capsule can significantly reduce serum CA125 level, increase serum MIS level, reduce uterine volume, relieve dysmenorrhea symptoms, and improve clinical efficacy and safety.
【作者单位】：宁波大学医学院附属医院妇产科;
【基金】：浙江省医药卫生科技计划基金资助项目(2014KYB 239)
【分类号】：R972

【参考文献】